Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.
Yoshihama T, Fukunaga K, Hirasawa A, Nomura H, Akahane T, Kataoka F, Yamagami W, Aoki D, Mushiroda T. Yoshihama T, et al. Oncotarget. 2018 Jul 3;9(51):29789-29800. doi: 10.18632/oncotarget.25712. eCollection 2018 Jul 3. Oncotarget. 2018. PMID: 30038720 Free PMC article.
A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Nanki Y, Nomura H, Iwasa N, Saotome K, Dozen A, Yoshihama T, Hirano T, Hashimoto S, Chiyoda T, Yamagami W, Kataoka F, Aoki D. Nanki Y, et al. Among authors: yoshihama t. Jpn J Clin Oncol. 2021 Jan 1;51(1):54-59. doi: 10.1093/jjco/hyaa140. Jpn J Clin Oncol. 2021. PMID: 32776094
Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
Iwasa-Inoue N, Nomura H, Kataoka F, Chiyoda T, Yoshihama T, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Morisada T, Hirasawa A, Aoki D. Iwasa-Inoue N, et al. Among authors: yoshihama t. Int J Clin Oncol. 2022 Feb;27(2):441-447. doi: 10.1007/s10147-021-02050-3. Epub 2021 Oct 14. Int J Clin Oncol. 2022. PMID: 34648082
21 results